Novo Nordisk announced today that Wegovy® (semaglutide injection) is now approved to reduce the risk of non-fatal myocardial ...

The risk is increased in patients with risk factors such as renal impairment. Intravenous administration of betablockers has been reported to cause potentially life-threatening hyperkalemia in ...